Interv Akut Kardiol. 2013;12(2):88-92

Prophylactic treatment of stable angina pectoris

Jaromír Hradec
3. interní klinika 1. LF UK a VFN, Praha

Treatment of stable angina pectoris (AP) has to be complex. It consists of necessary preventive measures, pharmacological therapy and

revascularization procedures, either catheterization or surgical. Pharmacological therapy and invasive revascularization procedures are

not competitive, but they are complementary. The article brings an overview of pharmacological treatment of stable AP. In all patients

secondary prevention measures has to be apllied, non-pharmacological as well as pharmacological ones. It is possible to divide formally

pharmacological treatment of stable AP into treatment influencing prognosis (antiplatelet drugs, statins, RAAS inhibitors and betablockers)

and treatment influencing symptoms (betablockers, ivabradine, calcium channel blockers, long-acting nitrates and metabolically acting drugs).

Betablockers as the only drugs improving both, the prognosis and symptoms, therefore they are the antianginal drugs of the first choice.

Keywords: stable angina pectoris, pharmacotherapy, antianginal drugs

Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hradec J. Prophylactic treatment of stable angina pectoris. Interv Akut Kardiol. 2013;12(2):88-92.
Download citation

References

  1. Hradec J, Bultas J, Želízko M. Stabilní angina pectoris. Doporučený diagnostický a léčebný postup České kardiologické společnosti. Cor Vasa 2010; 43: 543-561. Go to original source...
  2. Qaseen A, Fihn SD, Dallas P, et al. Management of patients with stable ischemic heart disease: Executive summary of a clinical practice guideline from the American College of Physicians, American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/ Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med 2012; available at: http://annals.org. Go to original source... Go to PubMed...
  3. Qaseen A, Fihn SD, Williams S, et al. Evaluation of patients with stable ischemic heart disease: Executive summary of a clinical practice guideline from the American College of Physicians, American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med 2012; available at: http://annals.org. Go to original source... Go to PubMed...
  4. Perk J, DeBaker G, Gohlke H, et al. on behalf of The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention Clinial Practice. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2012; 33: 1635-1701. Go to original source... Go to PubMed...
  5. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study (HOPE) invetigators. N Engl J Med 2000; 342: 145-153. Go to original source... Go to PubMed...
  6. Fox K. on behalf of the EUROPA Executive Committee. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: a randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. Go to original source... Go to PubMed...
  7. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
  8. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-49F. Go to original source... Go to PubMed...
  9. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I (f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-2536. Go to original source... Go to PubMed...
  10. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-816. Go to original source... Go to PubMed...
  11. Fox K., Ford I, Steg G, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30: 2185-2194. Go to original source... Go to PubMed...
  12. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coronary Artery Dis 2003; 14: 171-179. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.